Ruling out heart failure in primary-care: The cost-benefit of pre-screening using NT-proBNP and QRS width
- 1 November 2008
- journal article
- Published by Elsevier in International Journal of Cardiology
- Vol. 130 (3) , 426-437
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillationEuropean Heart Journal, 2006
- Early diagnosis of congestive heart failure: clinical utility of B-type natriuretic peptide testing associated with Doppler echocardiographyJournal of Cardiovascular Medicine, 2006
- What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?European Heart Journal, 2005
- Combined Use of Amino Terminal-Pro-Brain Natriuretic Peptide Levels and QRS Duration to Predict Left Ventricular Systolic Dysfunction in Patients With DyspneaThe American Journal of Cardiology, 2005
- Diagnostic and Prognostic Performance of N-Terminal ProBNP in Primary Care Patients With Suspected Heart FailureJournal of Cardiac Failure, 2005
- Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)European Heart Journal, 2005
- Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiographyJACC, 2004
- Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiographyJournal of the American Society of Echocardiography, 2003
- Utility of B-Natriuretic Peptide in Detecting Diastolic DysfunctionCirculation, 2002
- How to diagnose diastolic heart failureEuropean Heart Journal, 1998